GITR及其在免疫调节中的作用

糖皮质激素诱导的TNFR家族相关受体（GITR），也被称为TNFRSF18、AITR（人类）。静止T细胞低水平表达GITR，而CD4^＋CD25^＋调节性T细胞则呈高水平表达。GITR与其配体（GITRL）结合后会增强T细胞激活、增殖、分泌细胞因子、MAPKs和NF-κB激活效应、抑制CD4^＋CD25^＋Treg细胞的功能，从而加强效应性T细胞的活性，有利于增强抗肿瘤免疫和抗病毒免疫。随着生物学环境的变化，GITR激活Siva或者TRAF，起着促进或诱导凋亡的作用。     

Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD)

 By using homozygosity mapping and positional cloning, we have shown that adult-onset type II citrullinemia (CTLN2) is caused by mutations of the SLC25A13 gene, which is localized on chromosome 7q21.3 and encodes a mitochondrial solute carrier protein named citrin. So far, we have reported nine mutations, most of which cause loss of citrin, and we have established several methods for DNA diagnosis. These methods have shown that more than 90% of the patients diagnosed as suffering from CTLN2 by enzymatic analysis carry SLC25A13 mutations in both alleles, indicating that CTLN2 is caused by citrin deficiency. Furthermore, by using the same DNA diagnosis methods, we discovered that 70 neonates or infants suffering from a particular type of neonatal hepatitis carry the same SLC25A13 mutations. Since the symptoms of the neonates are different from those of the more severe CTLN2 and usually ameliorate without special treatment, we designated the neonatal disease neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). We conclude that citrin deficiency causes NICCD in neonates and CTLN2 in adults through the additional effects of genetic or environmental modifiers. Since the function of citrin, together with that of an isoform, aralar, was found to be as a mitochondrial aspartate glutamate carrier, the various symptoms of NICCD and CTLN2 may be understood as caused by defective aspartate export from the mitochondria to the cytosol and defects in the malate aspartate shuttle. It is, however, still difficult to understand the cause of the hepatic deficiency of argininosuccinate synthetase protein in CTLN2. Received: March 20, 2002 / Accepted: March 28, 2002     

Differential expression of binding sites for chemokine RANTES on human T lymphocytes

The C-C chemokine RANTES, a T lymphocyte chemoattractant, is considered an important mediator of inflammation, allergy, and host defense against HIV-1 infection. In this study, we investigated the modulation of binding of RANTES to T lymphocytes. Human peripheral blood CD3+ T cells, when freshly isolated from buffy-coat blood, expressed a considerable number of high-affinity binding sites for RANTES. These cells also showed significant chemotactic migration in response to RANTES in vitro. After 6–15 h incubation at 37°C, the binding of RANTES, but not of macrophage inflammatory protein-1α (MIP-1α) or of monocyte chemotactic protein-3 (MCP-3), consistently increased. Scatchard analyses indicated that the number of binding sites for RANTES increased about threefold by 15 h without any change in the affinity. The increase in RANTES binding was no longer detected by 24 h. This increase in the specific binding was mainly attributable to CD4⁺ T cells and was not associated with increased chemotactic activity of these cells in response to RANTES. Incubation with anti-CD3 antibody for 15 h markedly reduced the binding capability of T cells for RANTES and was associated with decreased chemotactic activity. On the other hand, when T cells were incubated with interleukin-2 (IL-2) for 1 week, the specific binding for all three C-C chemokines, RANTES, MIP-1α, and MCP-3 was markedly increased in comparison to cells cultured in the absence of IL-2. These results suggest that the expression of binding sites on T cells for RANTES is differentially modulated, indicating the existence of novel receptors for RANTES that do not bind MIP-1α.     

Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities

1. Download : Download high-res image (227KB)
2. Download : Download full-size image

     

小鼠趋化因子COL19Ig融合蛋白表达载体的构建、表达及鉴定

通过特异引物扩增出去掉终止密码的mCCL19编码序列，经酶切、亚克隆、拼接构建了真核表达载体pcDNA3．1-CCL19Ig，酶切和测序鉴定插入序列；将重组质粒转染CHO细胞进行体外表达，通过RT—PCR、Western blot鉴定目的基因的表达，利用趋化小室法测趋化活性。结果测序证实重组表达载体含mCCL19编码序列和人IgGI Fc段序列，其序列分别与GenBank中公布序列比对一致，IgG1-Fc段读码框未发生改变；Western blot结果证实转染了pcDNA3．1-mCEL19Ig的CHO细胞培养上清中有相对分子质量为38000的融合蛋白mCCL19Ig表达；体外趋化实验表明融合蛋白mCCL19Ig对小鼠脾细胞有趋化活性，且呈剂量依耐关系。     

人参皂苷Rg1与Rh1对树突状细胞表达HLA-DR、CD25、CD44、CD54、CD11c及E-selectin的影响

目的：观察人参皂苷Rg1和Rh1对树突状细胞（Dendritic cell，DC）表面分子CD25、HLA-DR、CD44、ICAM-1、CD11c及E-sclectin表达的影响。方法：用不同浓度的Rg1和Rh1分别加入成熟DC中，刺激一定时间后，用免疫组化法观察，并用图像分析法分析结果。结果：除E-selectin外，Rg1和Rh1均可不同程度地促进HLA—DR、CD25、CD11c、CD44和ICAM-1的表达。结论：Rg1、Rh1可增强DC表面促进T细胞活化的第一、二类信号系统分子的表达，提高其抗原递呈能力，并促进DC—T细胞簇的形成而活化初始T细胞。     

Galectin-3与CDC25B在胃癌中的表达及意义

目的 探讨半乳糖凝集素3 mRNA(Galectin-3)和细胞分裂周期蛋白25B mRNA(cell division cycle 25B,CDC25B)在胃癌中的表达及其与临床病理参数及预后的关系.方法 应用组织微阵列技术和原位杂交法检测220例胃癌组织和31份正常胃黏膜组织中Galectin-3 mRNA和CDC25B mRNA 的表达情况.结果 220例胃癌中Galectin-3 mRNA和CDC25B mRNA的阳性表达率分别为58.6%、54.1%;Galectin-3 mRNA表达与肿瘤大小、TNM(tumor,lymph node,metastasis)分期、浸润深度、脉管侵犯、淋巴结转移及远处转移呈正相关;CDC25B mRNA表达也与肿瘤大小、TNM分期、脉管侵犯、淋巴结转移及远处转移呈正相关;Galectin-3 mRNA表达与CDC25B mRNA表达呈正相关;Galectim3 mRNA和CDC25B mRNA阳性表达病例的平均生存时间和5年生存率均明显低于阴性表达的病例.结论 Galectin-3 和CDC25B基因的表达促进了胃癌的发生和发展,是指导临床治疗及评估预后的有效指标.     

抗人CD154单抗轻重链可变区基因克隆与序列分析

目的:克隆抗人CD154抗体轻重链可变区基因,并分析其核苷酸序列,为基因工程抗体的构建奠定基础。方法:从分泌能抑制免疫反应的抗人CD154单克隆抗体杂交瘤细胞株 7E8中提取总RNA,合成cDNA第一链后,经PCR扩增获得抗人CD154单抗轻链可变区 (VL)和重链可变区 (VH)基因,分别克隆入pUC18载体,并进行序列分析。结果:①抗体的轻链可变区基因全长为 341bp,编码113个氨基酸,归属于Ig的Vκ2基因,氨基酸序列分析结果显示轻链可变区含有明确的 4个骨架区和 3个抗原决定簇互补区,在第 2 3位和第 93位氨基酸为半胱氨酸,是与抗体二硫键形成有关的两个特征性氨基酸;②抗体的重链可变区基因全长为 354bp,编码118个氨基酸,归属于小鼠IgVH基因,D、J区基因分别属于DSP2.9和JH2,氨基酸序列分析结果显示,重链可变区含有明确的 4个骨架区和 3个抗原决定簇互补区,在第 2 3和第 97位氨基酸为半胱氨酸,是与抗体二硫键形成有关的两个特征性氨基酸。结论:经核苷酸序列分析证明所克隆的基因分别为抗体的轻、重链可变区基因.     

趋化性细胞因子对人Tc1和Tc2细胞内Ca~(2+)浓度变化的影响

为了探讨趋化性细胞因子在体外对人Tc1和Tc2亚群细胞内Ca2 + 浓度变化的影响 ,从PBMC中分离纯化CD8+ T细胞 ,在特定细胞因子及细胞因子抗体作用下 ,体外定向诱导出能长期培养的Tc1和Tc2细胞系 ,用免疫荧光染色结合流式细胞术分析对其进行鉴定后 ,通过流式细胞术检测在趋化性细胞因子刺激前后 ,细胞内Ca2 + 浓度的变化。发现受SDF 1作用后 ,Tc1及Tc2细胞内Ca2 + 浓度变化均不明显 ,而IP 10刺激后 ,Tc1及Tc2细胞内Ca2 + 水平在短时间内明显上调 ,且在Tc1胞内的上升幅度远高于Tc2细胞 ,在MIP 1β刺激后 ,也观察到类似趋势 ;受Eotaxin刺激后 ,Tc1及Tc2细胞内Ca2 + 水平均有微小上升 ,在Tc2细胞内的上升幅度略高于Tc1细胞。说明Tc1和Tc2细胞受趋化性细胞因子作用后 ,细胞内Ca2 + 浓度有不同程度的变化 ,且与趋化性细胞因子受体的表达呈现一定的相关性。     

Induction of B cell costimulatory function by recombinant murine CD40 ligand

T cell-dependent regulation of B cell growth and differentiation involves an interaction between CD40, a B cell surface molecule, and the CD40 ligand (CD40L) which is expressed on activated CD4⁺ T cells. In the current study, we show that recombinant membrane-bound murine CD40L induces B cells to express costimulatory function for the proliferation of CD4⁺ Tcells. CD40L- or lipopolysaccharide (LPS)-activated, but not control-cultured B cells were strong costimulators of anti-CD3 or alloantigen-dependent T cell responses. The molecular interactions responsible for the increased costimulatory functions were examined by analyzing the activated B cells for changes in the expression of two costimulatory molecules, B7 and heat-stable antigen (HSA), as well as by the use of antagonists of B7 and HSA (CTLA4.Fc and 20C9, respectively). The expression of both B7 and HSA was enhanced on B cells activated with LPS. As observed in previous studies, the costimulatory activity of the LPS-activated B cells was dependent on both B7 and HSA and was completely inhibited in the presence of a combination of CTLA4.Fc and 20C9. In contrast, activation of B cells with CD40L induced the expression of B7 but did not enhance the expression of HSA. In addition the costimulatory activity of the CD40L-activated B cells was partially, but not completely, inhibited by the combination of CTLA4.Fc and 20C9. These results demonstrate that CD40L regulates costimulatory function of B cells in part by inducing the expression of B7 and suggest that CD40L-activated B cells express an additional costimulatory activity that is not associated with LPS-activated B cells.